RecruitingPhase 1Phase 2NCT05308264

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Sponsor

Rigel Pharmaceuticals

Enrollment

86 participants

Start Date

Sep 12, 2022

Study Type

INTERVENTIONAL

Conditions

Low Risk Myelodysplastic Syndromes

Summary

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called R906289 Monosodium (R289 Na) for people with low risk myelodysplastic syndromes. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGR906289 Monosodium (R289 Na)

Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)

Locations(15)

University of California, Los Angeles

Los Angeles, California, United States

University of California, Irvine

Orange, California, United States

Stanford Cancer Institute

Palo Alto, California, United States

University of Miami

Miami, Florida, United States

Mount Sinai Medical Center

Miami Beach, Florida, United States

WashU Medicine

St Louis, Missouri, United States

Oncology Clinical Research Referral Office

Hackensack, New Jersey, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Ichan School of Medicine at Mount Sinai

New York, New York, United States

Duke Cancer Institute

Durham, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

University of Texas, Southwestern

Dallas, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Intermountain Healthcare

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05308264

Related Trials

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

NCT066702223 locations

Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS

NCT066145951 location